Literature DB >> 23338972

NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism.

Haifeng Zhu1, Deeksha Vishwamitra, Choladda V Curry, Roxsan Manshouri, Lixia Diao, Aarish Khan, Hesham M Amin.   

Abstract

NPM-ALK chimeric oncogene is aberrantly expressed in an aggressive subset of T-cell lymphomas that frequently occurs in children and young adults. The mechanisms underlying the oncogenic effects of NPM-ALK are not completely elucidated. Inducible nitric oxide synthase (iNOS) promotes the survival and maintains the malignant phenotype of cancer cells by generating NO, a highly active free radical. We tested the hypothesis that iNOS is deregulated in NPM-ALK(+) T-cell lymphoma and promotes the survival of this lymphoma. In line with this possibility, an iNOS inhibitor and NO scavenger decreased the viability, adhesion, and migration of NPM-ALK(+) T-cell lymphoma cells, and an NO donor reversed these effects. Moreover, the NO donor salvaged the viability of lymphoma cells treated with ALK inhibitors. In further support of an important role of iNOS, we found iNOS protein to be highly expressed in NPM-ALK(+) T-cell lymphoma cell lines and in 79% of primary tumours but not in human T lymphocytes. Although expression of iNOS mRNA was identified in NPM-ALK(+) T-cell lymphoma cell lines and tumours, iNOS mRNA was remarkably elevated in T lymphocytes, suggesting post-transcriptional regulation. Consistently, we found that miR-26a contains potential binding sites and interacts with the 3'-UTR of iNOS. In addition, miR-26a was significantly decreased in NPM-ALK(+) T-cell lymphoma cell lines and tumours compared with T lymphocytes and reactive lymph nodes. Restoration of miR-26a in lymphoma cells abrogated iNOS protein expression and decreased NO production and cell viability, adhesion, and migration. Importantly, the effects of miR-26a were substantially attenuated when the NO donor was simultaneously used to treat lymphoma cells. Our investigation of the mechanisms underlying the decrease in miR-26a in this lymphoma revealed novel evidence that STAT3, a major downstream substrate of NPM-ALK tyrosine kinase activity, suppresses MIR26A1 gene expression.
Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23338972      PMCID: PMC3940725          DOI: 10.1002/path.4171

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  58 in total

1.  Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer.

Authors:  S H Aaltoma; P K Lipponen; V M Kosma
Journal:  Anticancer Res       Date:  2001 Jul-Aug       Impact factor: 2.480

2.  Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas.

Authors:  M Vakkala; K Kahlos; E Lakari; P Pääkkö; V Kinnula; Y Soini
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

3.  NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.

Authors:  Roberto Chiarle; Jerald Z Gong; Ilaria Guasparri; Anna Pesci; Jonjing Cai; Jian Liu; William J Simmons; Girish Dhall; Jennifer Howes; Roberto Piva; Giorgio Inghirami
Journal:  Blood       Date:  2002-11-07       Impact factor: 22.113

Review 4.  Role of nitric oxide in carcinogenesis and tumour progression.

Authors:  P K Lala; C Chakraborty
Journal:  Lancet Oncol       Date:  2001-03       Impact factor: 41.316

5.  Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.

Authors:  Alberto Zamo; Roberto Chiarle; Roberto Piva; Jennifer Howes; Yan Fan; Marco Chilosi; David E Levy; Giorgio Inghirami
Journal:  Oncogene       Date:  2002-02-07       Impact factor: 9.867

6.  The effect of nitric oxide on cell respiration: A key to understanding its role in cell survival or death.

Authors:  B Beltrán; A Mathur; M R Duchen; J D Erusalimsky; S Moncada
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

7.  IL-4 and interferon gamma regulate expression of inducible nitric oxide synthase in chronic lymphocytic leukemia cells.

Authors:  M C Levesque; M A Misukonis; C W O'Loughlin; Y Chen; B E Beasley; D L Wilson; D J Adams; R Silber; J B Weinberg
Journal:  Leukemia       Date:  2003-02       Impact factor: 11.528

8.  The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts.

Authors:  A Wellmann; V Doseeva; W Butscher; M Raffeld; P Fukushima; M Stetler-Stevenson; K Gardner
Journal:  FASEB J       Date:  1997-10       Impact factor: 5.191

9.  Ubiquitination of inducible nitric oxide synthase is required for its degradation.

Authors:  Pawel J Kolodziejski; Aleksandra Musial; Ja-Seok Koo; N Tony Eissa
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-09       Impact factor: 11.205

10.  Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB.

Authors:  Zhiyuan Yu; Wenzheng Zhang; Bruce C Kone
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

View more
  11 in total

Review 1.  Dysregulation of microRNAs and their association in the pathogenesis of T-cell lymphoma/leukemias.

Authors:  Sho Ikeda; Hiroyuki Tagawa
Journal:  Int J Hematol       Date:  2014-02-25       Impact factor: 2.490

Review 2.  Understanding the tumour micro-environment communication network from an NOS2/COX2 perspective.

Authors:  Debashree Basudhar; Gaurav Bharadwaj; Veena Somasundaram; Robert Y S Cheng; Lisa A Ridnour; Mayumi Fujita; Stephen J Lockett; Stephen K Anderson; Daniel W McVicar; David A Wink
Journal:  Br J Pharmacol       Date:  2018-11-06       Impact factor: 8.739

3.  The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphoma.

Authors:  Deeksha Vishwamitra; Choladda V Curry; Serhan Alkan; Yao-Hua Song; Gary E Gallick; Ahmed O Kaseb; Ping Shi; Hesham M Amin
Journal:  Mol Cancer       Date:  2015-02-25       Impact factor: 27.401

Review 4.  Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas.

Authors:  Coralie Hoareau-Aveilla; Fabienne Meggetto
Journal:  Cancers (Basel)       Date:  2017-08-03       Impact factor: 6.639

5.  Leishmania (Leishmania) amazonensis induces macrophage miR-294 and miR-721 expression and modulates infection by targeting NOS2 and L-arginine metabolism.

Authors:  Sandra Marcia Muxel; Maria Fernanda Laranjeira-Silva; Ricardo Andrade Zampieri; Lucile Maria Floeter-Winter
Journal:  Sci Rep       Date:  2017-03-09       Impact factor: 4.379

Review 6.  Systems and Synthetic microRNA Biology: From Biogenesis to Disease Pathogenesis.

Authors:  Hironori Matsuyama; Hiroshi I Suzuki
Journal:  Int J Mol Sci       Date:  2019-12-24       Impact factor: 5.923

Review 7.  Oxidative Stress and Inflammation in Cardiovascular Diseases and Cancer: Role of Non-coding RNAs.

Authors:  Pieterjan Ginckels; Paul Holvoet
Journal:  Yale J Biol Med       Date:  2022-03-31

8.  microRNA-146a promotes mycobacterial survival in macrophages through suppressing nitric oxide production.

Authors:  Miao Li; Jinli Wang; Yimin Fang; Sitang Gong; Meiyu Li; Minhao Wu; Xiaomin Lai; Gucheng Zeng; Yi Wang; Kun Yang; Xi Huang
Journal:  Sci Rep       Date:  2016-03-30       Impact factor: 4.379

9.  Concentration of circulating miRNA-containing particles in serum enhances miRNA detection and reflects CRC tissue-related deregulations.

Authors:  Abdou ElSharawy; Christian Röder; Thomas Becker; Jens K Habermann; Stefan Schreiber; Philip Rosenstiel; Holger Kalthoff
Journal:  Oncotarget       Date:  2016-11-15

Review 10.  Arginine Metabolism and Its Potential in Treatment of Colorectal Cancer.

Authors:  Tao Du; Junyi Han
Journal:  Front Cell Dev Biol       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.